Cencora, Inc. (NYSE:COR) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Cencora, Inc. (NYSE:COR) have been given a consensus rating of “Moderate Buy” by the thirteen research firms that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $393.0833.

Several brokerages recently issued reports on COR. Evercore ISI set a $400.00 price target on shares of Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. UBS Group raised their price objective on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Barclays initiated coverage on shares of Cencora in a research note on Monday, December 8th. They issued an “overweight” rating and a $400.00 target price for the company. Wells Fargo & Company increased their price target on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Finally, JPMorgan Chase & Co. raised their price target on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th.

Cencora Price Performance

Shares of COR stock opened at $353.07 on Friday. The stock’s fifty day simple moving average is $348.49 and its 200 day simple moving average is $321.90. Cencora has a one year low of $237.71 and a one year high of $377.54. The firm has a market cap of $68.49 billion, a price-to-earnings ratio of 44.41, a P/E/G ratio of 1.68 and a beta of 0.66. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same period last year, the business earned $3.34 earnings per share. The business’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, analysts expect that Cencora will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Insider Activity

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the sale, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This represents a 12.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at $23,669,713.98. The trade was a 7.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 20,316 shares of company stock worth $7,151,265. 10.80% of the stock is owned by corporate insiders.

Institutional Trading of Cencora

Several hedge funds have recently modified their holdings of COR. Atlantic Edge Private Wealth Management LLC increased its stake in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares during the last quarter. Optima Capital LLC acquired a new position in Cencora during the fourth quarter valued at approximately $31,000. IAG Wealth Partners LLC acquired a new position in Cencora during the third quarter valued at approximately $30,000. Cloud Capital Management LLC bought a new stake in Cencora in the third quarter valued at approximately $31,000. Finally, Caitlin John LLC acquired a new stake in Cencora in the third quarter worth $31,000. 97.52% of the stock is owned by institutional investors.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.